Author: sseifirad

Arrhythmia and Electrophysiology, Atrial Fibrillation, Cardiogenic shock, Cardiomyopathies, Cardiovascular Prevention, Cardiovascular Surgery, Heart Failure, News, policy, Stroke, Structural Heart Disease, Sudden Cardiac Death, Syncope, Valvular Heart Disease

The Sarcomeric Human Cardiomyopathy Registry: Race Associated with Disease Expression and Clinical Outcomes Among Patients with Hypertrophic Cardiomyopathy

by sseifirad 0
Hypertrophic cardiomyopathy (HCM) is the most common inherited genetic disorder of the myocardium, and the number one culprit of sudden cardiac death in athletes,... Read more.
Arrhythmia and Electrophysiology, Atrial Fibrillation, Clinical Trials, ESC 2019, News, Prevention, Thrombosis

ADRIFT Trial: Low-Dose Rivaroxaban is Superior to Dual Antiplatelet Therapy for Controlling Thrombin Generation after Left Atrial Appendage Closure in Atrial Fibrillation Patients

by sseifirad 0
According to the results of Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Treated with Left Atrial Appendage Closure (ADRIFT)... Read more.